OneMedNet collaborates with Bayer’s AI Innovation Platform to accelerate healthcare AI development
Press releases may be edited for formatting or style | December 04, 2024
Business Affairs
OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet” or the “Company”), a Real-World Data (RWD) platform — has announced its collaboration with Bayer’s AI Innovation Platform (AIIP). By joining AIIP, the partnership aims to empower the developer teams of healthcare organizations and startups in building scalable and compliant AI-powered medical imaging software products
“We are thrilled to join forces with Bayer’s AI Innovation Platform,” said Aaron Green, CEO & President of OneMedNet. “This collaboration allows us to combine our regulatory-grade real-world data platform, which aggregates data from our provider network of over 1,400 healthcare provider facilities, with Bayer’s innovative AIIP. Together, we aim to empower developers to create advanced AI solutions that can significantly improve patient outcomes.”
The partnership underscores the importance of collaboration in addressing the diverse requirements of healthcare AI development. By integrating OneMedNet’s robust iRWDä platform with Bayer’s AIIP, developers will have access to comprehensive tools and the precise datasets necessary for creating effective and compliant AI healthcare applications.
About OneMedNet Corporation
OneMedNet provides innovative solutions that are designed to unlock the significant value contained within the Real-World Data (“RWD”) repositories of over 1,400 healthcare system and provider sites that currently comprise its iRWD™ network. OneMedNet’s proprietary iRWD™ platform provides secure, comprehensive management of diverse clinical data types, including electronic health records, ECGs, EEGs, prescriptions, physician notes, laboratory results, and uniquely, medical imaging. Employing its robust iRWD™ platform, the Company securely de-identifies, searches, and curates the clinical data, bringing a wealth of internal and third-party research opportunities to its drug, medical device and imaging/diagnostic AI development customers.
OneMedNet’s platform is designed to address diverse clinical requirements across various domains, such as rare diseases, central nervous system disorders, oncology, cardiology and women’s health. The Company is committed to delivering precise and robust research support services that span the entire continuum of care. This commitment is a cornerstone of OneMedNet’s strategy to enhance patient outcomes and help pave the next wave of healthcare innovation. For more information, please visit www.onemednet.com.
|
|
|
You Must Be Logged In To Post A Comment
|
